Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

被引：210
|
作者：
Chen, Jiang [1 ]
Jin, Renan [1 ]
Zhao, Jie [1 ]
Liu, Jinghua [1 ]
Ying, Hanning [1 ]
Yan, Han [1 ]
Zhou, Senjun [1 ]
Liang, Yuelong [1 ]
Huang, Diyu [1 ]
Liang, Xiao [1 ]
Yu, Hong [1 ]
Lin, Hui [1 ]
Cai, Xiujun [1 ]
机构：
[1] Zhejiang Univ, Dept Gen Surg, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China
来源：
CANCER LETTERS | 2015年 / 367卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG SIGNALING PATHWAY; ALPHA-B-CRYSTALLIN; LIVER-CANCER CELLS; PHASE-III; PROMOTES METASTASIS; DEPENDENT MECHANISM; PLUS SORAFENIB; BREAST-CANCER; UP-REGULATION;
D O I：
10.1016/j.canlet.2015.06.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 50 条
  • [1] The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
    Xia, Shunjie
    Pan, Yu
    Liang, Yuelong
    Xu, Junjie
    Cai, Xiujun
    EBIOMEDICINE, 2020, 51
  • [2] Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms
    Dahiya, Mandeep
    Dureja, Harish
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (05) : 286 - 301
  • [3] Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
    Nishida, Naoshi
    Kitano, Masayuki
    Sakurai, Toshiharu
    Kudo, Masatoshi
    DIGESTIVE DISEASES, 2015, 33 (06) : 771 - 779
  • [4] Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
    Zhang, Zhi
    He, Cheng-Zu
    Qin, Ya-Qin
    Liao, Jian-Jun
    Huang, Shang-Tao
    Mo, Steven
    Li, Hong-Mian
    Lin, Jian-Yan
    AGING-US, 2020, 12 (23): : 24255 - 24269
  • [5] Mechanisms of sorafenib resistance in hepatocellular carcinoma
    Liang, Yuanjing
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (08)
  • [6] The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
    Chow, Ariel Ka-Man
    Ng, Lui
    Lam, Colin Siu-Chi
    Wong, Sunny Kit-Man
    Wan, Timothy Ming-Hun
    Cheng, Nathan Shiu-Man
    Yau, Thomas Chung-Cheung
    Poon, Ronnie Tung-Ping
    Pang, Roberta Wen-Chi
    PLOS ONE, 2013, 8 (11):
  • [7] Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma
    Li, Heping
    Hu, Jie
    Qiu, Lijie
    Wu, Yijiang
    Zhong, Baiyin
    Ye, Rong
    Xie, Binhui
    ANTI-CANCER DRUGS, 2024, 35 (01) : 55 - 62
  • [8] Elucidation of the molecular mechanisms mediating sorafenib-resistance in Hepatocellular carcinoma
    Vishnoi, Kanchan
    Ke, Rong
    Kumar, Randhir
    Viswakarma, Navin
    Rana, Ajay
    Rana, Basabi
    CANCER RESEARCH, 2020, 80 (16)
  • [9] EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
    Ezzoukhry, Zakaria
    Louandre, Christophe
    Trecherel, Eric
    Godin, Corinne
    Chauffert, Bruno
    Dupont, Sebastien
    Diouf, Momar
    Barbare, Jean-Claude
    Maziere, Jean-Claude
    Galmiche, Antoine
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (12) : 2961 - 2969
  • [10] Metallothionein-3: Potential therapeutic target for sorafenib resistance in hepatocellular carcinoma
    Rodrigo, Miguel A. Merlos
    Michalkova, Hana
    Smidova, Veronika
    Casar, Berta
    de los Rios, Vivian
    Casal, Jose I.
    Serrano Macia, Marina
    Fernandez Ramos, David
    Martinez Chantar, Maria L.
    Adam, Vojtech
    Heger, Zbynek
    ANNALS OF ONCOLOGY, 2021, 32 : S323 - S323
12345